One year of complete clinical response in a metastatic breast cancer patient treated with a combination of lapatinib and gemcitabine.
The treatment of metastatic breast cancer is challenging. We recently assisted in the development of targeted therapies (in combination with chemotherapy or as monotherapy) that have improved results for selected groups of patients. Lapatinib is a dual tyrosine kinase inhibitor that has shown efficacy in breast cancer. Consequently, its use has been approved, in combination with capecitabine, for the treatment of disease positive for the human epidermal growth factor receptor. Here, we present a case of complete clinical response to a combination of lapatinib and gemcitabine that was maintained for 1 year.
Gasent Blesa
J M
JM
Hospital de Dénia, Marinasalud, Partida de Beniadlà, Dénia Alacant, Spain. joanmagasent@telefonica.net
Laforga Canales
J
J
Candel
V Alberola
VA
Cancer Res. 1991 Nov 15;51(22):6110-7
1718594
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
Breast. 2000 Dec;9(6):338-42
14965758
Cancer Res. 1997 Nov 1;57(21):4838-48
9354447
Oncogene. 2004 Jan 22;23(3):646-53
14737100
Cancer Res. 2008 Jan 15;68(2):571-9
18199554
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Mol Cancer Ther. 2001 Dec;1(2):85-94
12467226
Oncology. 2002;62(1):2-8
11810037
Cancer Res. 2004 Sep 15;64(18):6652-9
15374980
J Natl Cancer Inst. 2008 May 21;100(10):694-5
18477795
Clin Cancer Res. 2000 May;6(5):2053-63
10815932
PLoS One. 2008 Aug 26;3(8):e3065
18725974
Oncogene. 2002 Sep 12;21(41):6255-63
12214266
Biochemistry (Mosc). 2000 Jan;65(1):59-67
10702641